ArticleCancer cell2014
Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer.Nature communications · 2026Article
- Multi-transcriptomics predicts clinical outcome in systemically untreated breast cancer patients with extensive follow-up.Breast cancer research : BCR · 2025Article
- miR-3154 promotes glioblastoma proliferation and metastasis via targeting TP53INP1.Cell division · 2024Article
- MIR937 amplification potentiates ovarian cancer progression by attenuating FBXO16 inhibition on ULK1-mediated autophagy.Cell death & disease · 2024Article
- A comprehensive analysis of the prognostic characteristics of microRNAs in breast cancer.Frontiers in genetics · 2024Article
- Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer.Journal of translational medicine · 2023Article
- Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.Frontiers in immunology · 2023Article
- Systematic Investigation of the Diagnostic and Prognostic Impact of LINC01087 in Human Cancers.Cancers · 2022Article
- Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies.Molecular therapy oncolytics · 2022Review
- microRNA-569 inhibits tumor metastasis in pancreatic cancer by directly targeting NUSAP1.Aging · 2022Article
- Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance.Cancers · 2022Article
- Hypermethylation ofEXCLI journal · 2022Article
- RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site.Cell reports · 2021Article
- Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.Cancer research · 2020Article
- 9q34 & 16p13 chromosome duplications in autism.AME case reports · 2020Article
- MiR-212-3p suppresses high-grade serous ovarian cancer progression by directly targeting MAP3K3.American journal of translational research · 2020Article
- miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.Cell reports · 2019Article
- Downregulation of microRNA-3934-5p induces apoptosis and inhibits the proliferation of neuroblastoma cells by targeting TP53INP1.Experimental and therapeutic medicine · 2019Article
- Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells.Journal of ovarian research · 2019Article
- Prediction of Disease-related microRNAs through Integrating Attributes of microRNA Nodes and Multiple Kinds of Connecting Edges.Molecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 5 institutions in 3 countries.
Pradeep Chaluvally-RaghavanDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. Electronic address: pcraghavan@mdanderson.org.
Fan ZhangDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Sunila PradeepDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Mark P HamiltonDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Xi ZhaoDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital, the Norwegian Radium Hospital, 0424 Oslo, Norway; The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, 0424 Oslo, Norway.
Rajesha RupaimooleDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Tyler MossDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Yiling LuDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Shuangxing YuDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Chad V PecotDepartment of Thoracic, Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Miriam R AureDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital, the Norwegian Radium Hospital, 0424 Oslo, Norway; The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, 0424 Oslo, Norway.
Sylvain PeugetINSERM U1068, CRCM, Cell Stress, Marseille F-13009, France; Institut Paoli-Calmettes, 13273 Marseille Cedex 9, France; UMR7258, CNRS, Aix-Marseille University, Marseille F-13009, France.
Cristian Rodriguez-AguayoDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Hee-Dong HanCenter for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Dong ZhangDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Avinashnarayan VenkatanarayanDepartment of Biochemistry and Molecular Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Marit KrohnDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital, the Norwegian Radium Hospital, 0424 Oslo, Norway; The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, 0424 Oslo, Norway.
Vessela N KristensenDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital, the Norwegian Radium Hospital, 0424 Oslo, Norway; The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, 0424 Oslo, Norway.
Mihai GageaDepartment of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Prahlad RamDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Wenbin LiuDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Gabriel Lopez-BeresteinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Center for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Philip L LorenziDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Anne-Lise Børresen-DaleDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital, the Norwegian Radium Hospital, 0424 Oslo, Norway; The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, 0424 Oslo, Norway.
Koei ChinDepartment of Biomedical Engineering, School of Medicine, Oregon Health and Science University, Portland, OR 97239, USA.
Joe GrayDepartment of Biomedical Engineering, School of Medicine, Oregon Health and Science University, Portland, OR 97239, USA.
Nelson J DusettiINSERM U1068, CRCM, Cell Stress, Marseille F-13009, France; Institut Paoli-Calmettes, 13273 Marseille Cedex 9, France; UMR7258, CNRS, Aix-Marseille University, Marseille F-13009, France.
Sean E McGuireDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Elsa R FloresDepartment of Biochemistry and Molecular Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Anil K SoodDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Center for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Gordon B MillsDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. Electronic address: gmills@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USOslo University Hospital · NOCentre National de la Recherche Scientifique · FROregon Health & Science University · USBaylor College of Medicine · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MUNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0MTissue and Outcomes CoreP50CA058207 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRAY, JOE W. · 1992 to 2012
$32.7MTargeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0MTUMOR SUPPRESSOR GENES IN BREAST CANCER DEVELOPMENTP50CA058183 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI OSBORNE, C KENT · 1992 to 2012
$30.9MSystems-Based Predictions of Responses to Cancer TherapyU54CA112970 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI TOMLIN, CLAIRE J · 2004 to 2014
$27.1MTexas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2010 to 2014
$12.4MThe Role of Aberrant Splicing of EVl1 in Ovarian Cancer PathophysiologyR01CA123219 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MILLS, GORDON B., NANJUNDAN, MEERA · 2008 to 2012
$2.2MNCI NIH HHS 2P50CA083639-11NCI NIH HHS 5P50CA058183-17NCI NIH HHS 5R01CA123219-01NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA058183NCI NIH HHS P50 CA058207NCI NIH HHS P50 CA083639NCI NIH HHS P50CA083639NCI NIH HHS P50 CA098258NCI NIH HHS P50CA098258NCI NIH HHS P50CA58207NCI NIH HHS R01 CA123219NCI NIH HHS U54 CA112970NCI NIH HHS U54CA112970NCI NIH HHS U54 CA151668
Abstract
Small noncoding miRNAs represent underexplored targets of genomic aberrations and emerging therapeutic targets. The 3q26.2 amplicon is among the most frequent genomic aberrations in multiple cancer lineages including ovarian and breast cancers. We demonstrate that hsa-miR-569 (hereafter designated as miR569), which is overexpressed in a subset of ovarian and breast cancers, at least in part due to the 3q26.2 amplicon, alters cell survival and proliferation. Downregulation of TP53INP1 expression by miR569 is required for the effects of miR569 on survival and proliferation. Targeting miR569 sensitizes ovarian and breast cancer cells overexpressing miR569 to cisplatin by increasing cell death both in vitro and in vivo. Thus targeting miR569 could potentially benefit patients with the 3q26.2 amplicon and subsequent miR569 elevation.
Indexed as
AnimalsAntineoplastic AgentsBreast NeoplasmsCarrier ProteinsCell Line, TumorCell ProliferationCell SurvivalChromosomes, Human, Pair 3CisplatinFemaleGene AmplificationGene DuplicationGene Expression Regulation, NeoplasticHeat-Shock ProteinsHumansMiceAntineoplastic AgentsCarrier ProteinsCisplatinHeat-Shock ProteinsMicroRNAsMIRN-569 microRNA, humanMIRN-569 microRNA, mouseNuclear ProteinsTP53INP1 protein, humantumor protein 53-induced nuclear protein 1, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.